Health Guard plans dual listing to fund HPV vaccine fight
After a Beijing IPO last year, the loss-making biotech has also filed for a Hong Kong listing to better compete in the crowded market for HPV vaccines Key Takeaways: Beijing…
FAST NEWS: Zai Lab Acquires Exclusive Greater China License for Cervical Cancer Drug
The latest: Biotech drug maker Zai Lab Ltd. (9688.HK; ZLAB.US) announced on Tuesday that one of its subsidiaries has obtained an exclusive license to develop and commercialize Seagen Inc.’s (SGEN.US) cervical cancer…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - Margins ring alarm bells as 160 Health readies IPO
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
- Bayzed joins IPO quest as medical rivalry heats up
- Payment app Lianlian seeks IPO relief from cash crunch
- Baiwang eyes Hong Kong IPO to support its money-hungry loan facilitation business
